Recombinant human thyroid-stimulating hormone (Thyrogen) in thyroid cancer follow up: experience at a single institution.

Abstract

BACKGROUND Recombinant human thyroid-stimulating hormone (Thyrogen; Genzyme Corporation, Cambridge, MA, USA) (rhTSH)-stimulated serum thyroglobulin (Tg) (stim-Tg) and (131)I whole-body scanning (WBS) have been reported to allow follow up of patients with thyroid cancer without the symptoms of thyroxine withdrawal and with equivalent diagnostic information… (More)
DOI: 10.1111/j.1445-5994.2008.01735.x

Topics

Cite this paper

@article{Wong2009RecombinantHT, title={Recombinant human thyroid-stimulating hormone (Thyrogen) in thyroid cancer follow up: experience at a single institution.}, author={Rebecca K. S. Wong and Duncan J Topliss and Leon A. Bach and Peter Shane Hamblin and Victor Kalff and Fiona Long and Jim R. Stockigt}, journal={Internal medicine journal}, year={2009}, volume={39 3}, pages={156-63} }